Copyright Reports & Markets. All rights reserved.

Global Klebsiella Pneumoniae Infection Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Klebsiella Pneumoniae Infection Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Klebsiella Pneumoniae Infection Drug Market Size Growth Rate by Product
      • 1.4.2 ATI-1503
      • 1.4.3 CA-824
      • 1.4.4 CC-1807
      • 1.4.5 Cefiderocol
      • 1.4.6 Debio-1454
      • 1.4.7 EBX-004
      • 1.4.8 Others
    • 1.5 Market by End User
      • 1.5.1 Global Klebsiella Pneumoniae Infection Drug Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Klebsiella Pneumoniae Infection Drug Market Size
      • 2.1.1 Global Klebsiella Pneumoniae Infection Drug Revenue 2014-2025
      • 2.1.2 Global Klebsiella Pneumoniae Infection Drug Sales 2014-2025
    • 2.2 Klebsiella Pneumoniae Infection Drug Growth Rate by Regions
      • 2.2.1 Global Klebsiella Pneumoniae Infection Drug Sales by Regions
      • 2.2.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Klebsiella Pneumoniae Infection Drug Sales by Manufacturers
      • 3.1.1 Klebsiella Pneumoniae Infection Drug Sales by Manufacturers
      • 3.1.2 Klebsiella Pneumoniae Infection Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Klebsiella Pneumoniae Infection Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Klebsiella Pneumoniae Infection Drug Revenue by Manufacturers
      • 3.2.1 Klebsiella Pneumoniae Infection Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Klebsiella Pneumoniae Infection Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Klebsiella Pneumoniae Infection Drug Price by Manufacturers
    • 3.4 Klebsiella Pneumoniae Infection Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Klebsiella Pneumoniae Infection Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Klebsiella Pneumoniae Infection Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Klebsiella Pneumoniae Infection Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Klebsiella Pneumoniae Infection Drug Sales by Product
    • 4.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Product
    • 4.3 Klebsiella Pneumoniae Infection Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Klebsiella Pneumoniae Infection Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Klebsiella Pneumoniae Infection Drug by Countries
      • 6.1.1 North America Klebsiella Pneumoniae Infection Drug Sales by Countries
      • 6.1.2 North America Klebsiella Pneumoniae Infection Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Klebsiella Pneumoniae Infection Drug by Product
    • 6.3 North America Klebsiella Pneumoniae Infection Drug by End User

    7 Europe

    • 7.1 Europe Klebsiella Pneumoniae Infection Drug by Countries
      • 7.1.1 Europe Klebsiella Pneumoniae Infection Drug Sales by Countries
      • 7.1.2 Europe Klebsiella Pneumoniae Infection Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Klebsiella Pneumoniae Infection Drug by Product
    • 7.3 Europe Klebsiella Pneumoniae Infection Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Klebsiella Pneumoniae Infection Drug by Countries
      • 8.1.1 Asia Pacific Klebsiella Pneumoniae Infection Drug Sales by Countries
      • 8.1.2 Asia Pacific Klebsiella Pneumoniae Infection Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Klebsiella Pneumoniae Infection Drug by Product
    • 8.3 Asia Pacific Klebsiella Pneumoniae Infection Drug by End User

    9 Central & South America

    • 9.1 Central & South America Klebsiella Pneumoniae Infection Drug by Countries
      • 9.1.1 Central & South America Klebsiella Pneumoniae Infection Drug Sales by Countries
      • 9.1.2 Central & South America Klebsiella Pneumoniae Infection Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Klebsiella Pneumoniae Infection Drug by Product
    • 9.3 Central & South America Klebsiella Pneumoniae Infection Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Klebsiella Pneumoniae Infection Drug by Countries
      • 10.1.1 Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Countries
      • 10.1.2 Middle East and Africa Klebsiella Pneumoniae Infection Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Klebsiella Pneumoniae Infection Drug by Product
    • 10.3 Middle East and Africa Klebsiella Pneumoniae Infection Drug by End User

    11 Company Profiles

    • 11.1 Acies Bio doo
      • 11.1.1 Acies Bio doo Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Acies Bio doo Klebsiella Pneumoniae Infection Drug Products Offered
      • 11.1.5 Acies Bio doo Recent Development
    • 11.2 Appili Therapeutics
      • 11.2.1 Appili Therapeutics Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Products Offered
      • 11.2.5 Appili Therapeutics Recent Development
    • 11.3 Debiopharm International SA
      • 11.3.1 Debiopharm International SA Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Products Offered
      • 11.3.5 Debiopharm International SA Recent Development
    • 11.4 Evaxion Biotech ApS
      • 11.4.1 Evaxion Biotech ApS Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Products Offered
      • 11.4.5 Evaxion Biotech ApS Recent Development
    • 11.5 F. Hoffmann-La Roche Ltd
      • 11.5.1 F. Hoffmann-La Roche Ltd Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Products Offered
      • 11.5.5 F. Hoffmann-La Roche Ltd Recent Development
    • 11.6 FOB Synthesis Inc
      • 11.6.1 FOB Synthesis Inc Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Products Offered
      • 11.6.5 FOB Synthesis Inc Recent Development
    • 11.7 ImmunoClin Corp
      • 11.7.1 ImmunoClin Corp Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Products Offered
      • 11.7.5 ImmunoClin Corp Recent Development
    • 11.8 Innovation Pharmaceuticals Inc
      • 11.8.1 Innovation Pharmaceuticals Inc Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Products Offered
      • 11.8.5 Innovation Pharmaceuticals Inc Recent Development
    • 11.9 Kyorin Pharmaceutical Co Ltd
      • 11.9.1 Kyorin Pharmaceutical Co Ltd Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Products Offered
      • 11.9.5 Kyorin Pharmaceutical Co Ltd Recent Development
    • 11.10 Melinta Therapeutics Inc
      • 11.10.1 Melinta Therapeutics Inc Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Products Offered
      • 11.10.5 Melinta Therapeutics Inc Recent Development
    • 11.11 Nosopharm SAS
    • 11.12 Peptilogics Inc
    • 11.13 Pfizer Inc
    • 11.14 Phico Therapeutics Ltd
    • 11.15 Sarepta Therapeutics Inc
    • 11.16 Shionogi & Co Ltd
    • 11.17 Syntiron LLC
    • 11.18 Tetraphase Pharmaceuticals Inc

    12 Future Forecast

    • 12.1 Klebsiella Pneumoniae Infection Drug Market Forecast by Regions
      • 12.1.1 Global Klebsiella Pneumoniae Infection Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Klebsiella Pneumoniae Infection Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Klebsiella Pneumoniae Infection Drug Market Forecast by Product
      • 12.2.1 Global Klebsiella Pneumoniae Infection Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Klebsiella Pneumoniae Infection Drug Revenue Forecast by Product 2019-2025
    • 12.3 Klebsiella Pneumoniae Infection Drug Market Forecast by End User
    • 12.4 North America Klebsiella Pneumoniae Infection Drug Forecast
    • 12.5 Europe Klebsiella Pneumoniae Infection Drug Forecast
    • 12.6 Asia Pacific Klebsiella Pneumoniae Infection Drug Forecast
    • 12.7 Central & South America Klebsiella Pneumoniae Infection Drug Forecast
    • 12.8 Middle East and Africa Klebsiella Pneumoniae Infection Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Klebsiella Pneumoniae Infection Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Klebsiella Pneumoniae Infection Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Klebsiella Pneumoniae Infection Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Klebsiella Pneumoniae Infection Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Klebsiella Pneumoniae Infection Drug in these regions.
      This research report categorizes the global Klebsiella Pneumoniae Infection Drug market by top players/brands, region, type and end user. This report also studies the global Klebsiella Pneumoniae Infection Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Acies Bio doo
      Appili Therapeutics
      Debiopharm International SA
      Evaxion Biotech ApS
      F. Hoffmann-La Roche Ltd
      FOB Synthesis Inc
      ImmunoClin Corp
      Innovation Pharmaceuticals Inc
      Kyorin Pharmaceutical Co Ltd
      Melinta Therapeutics Inc
      Nosopharm SAS
      Peptilogics Inc
      Pfizer Inc
      Phico Therapeutics Ltd
      Sarepta Therapeutics Inc
      Shionogi & Co Ltd
      Syntiron LLC
      Tetraphase Pharmaceuticals Inc

      Market size by Product
      ATI-1503
      CA-824
      CC-1807
      Cefiderocol
      Debio-1454
      EBX-004
      Others
      Market size by End User
      Hospital
      Clinic
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Klebsiella Pneumoniae Infection Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Klebsiella Pneumoniae Infection Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Klebsiella Pneumoniae Infection Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Klebsiella Pneumoniae Infection Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Klebsiella Pneumoniae Infection Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Klebsiella Pneumoniae Infection Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now